1. Home
  2. MIRM vs TECH Comparison

MIRM vs TECH Comparison

Compare MIRM & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$65.05

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

HOLD

Current Price

$58.47

Market Cap

9.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
TECH
Founded
2018
1976
Country
United States
United States
Employees
355
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
9.5B
IPO Year
2019
1989

Fundamental Metrics

Financial Performance
Metric
MIRM
TECH
Price
$65.05
$58.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
14
Target Price
$87.55
$71.23
AVG Volume (30 Days)
560.0K
1.8M
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
0.55%
EPS Growth
N/A
N/A
EPS
N/A
0.49
Revenue
$471,794,000.00
$1,216,732,000.00
Revenue This Year
$53.78
$2.33
Revenue Next Year
$19.91
$7.05
P/E Ratio
N/A
$120.21
Revenue Growth
53.66
3.85
52 Week Low
$36.88
$46.01
52 Week High
$78.55
$79.28

Technical Indicators

Market Signals
Indicator
MIRM
TECH
Relative Strength Index (RSI) 36.47 41.76
Support Level $63.66 $58.75
Resistance Level $66.77 $61.20
Average True Range (ATR) 2.99 2.02
MACD -0.66 -0.49
Stochastic Oscillator 13.68 2.94

Price Performance

Historical Comparison
MIRM
TECH

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Share on Social Networks: